Bellevue Group’s United Therapeutics UTHR Stock Holding History

Bellevue Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.23M	Sell	2,077 -1,818	-47%	-$905K	0.03%	87
2025 Q4	$1.9M	Buy	3,895 +1,255	+48%	+$584K	0.04%	97
2025 Q3	$1.11M	Buy	+2,640	New	+$888K	0.02%	104
2023 Q1	–	Sell	-212	Closed	-$59K	–	173
2022 Q4	$59K	Sell	212 -89	-30%	-$22.5K	﹤0.01%	163
2022 Q3	$63K	Buy	301 +108	+56%	+$24.1K	﹤0.01%	165
2022 Q2	$45K	Buy	+193	New	+$39.2K	﹤0.01%	167
2018 Q1	–	Sell	-17,200	Closed	-$2.54M	–	135
2017 Q4	$2.54M	Sell	17,200 -4,400	-20%	-$559K	0.27%	72
2017 Q3	$2.53M	Buy	21,600 +13,800	+177%	+$1.76M	0.26%	74
2017 Q2	$1.01M	Hold	7,800	–	–	0.12%	103
2017 Q1	$1.06M	Hold	7,800	–	–	0.14%	101
2016 Q4	$1.12M	Buy	7,800 +1,500	+24%	+$192K	0.23%	80
2016 Q3	$744K	Hold	6,300	–	–	0.13%	107
2016 Q2	$667K	Sell	6,300 -13,000	-67%	-$1.45M	0.13%	107
2016 Q1	$2.33M	Buy	+19,300	New	+$2.44M	0.42%	72

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bellevue Group's UTHR Position: Q1 2026 in Review

Bellevue Group reduced its United Therapeutics (UTHR) stake by 47% in Q1 2026, selling an estimated $905K and leaving 2,077 shares worth $1.23M. The position accounts for 0.03% of the portfolio, ranked #87.

Bellevue Group first reported a position in UTHR in Q1 2016 and has held it in 14 quarters since. The position peaked at $2.54M in Q4 2017. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Bellevue Group held 2,077 shares of United Therapeutics worth $1.23M as of Q1 2026.
Bellevue Group sold 1,818 United Therapeutics shares in Q1 2026, an estimated $905K.
United Therapeutics made up 0.03% of Bellevue Group's portfolio in Q1 2026, its #87 holding.
Bellevue Group first reported a position in United Therapeutics in Q1 2016 and has held it in 14 quarters since.
Bellevue Group's United Therapeutics position peaked at $2.54M in Q4 2017.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.